Traders bought shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on weakness during trading hours on Thursday following insider selling activity. $183.59 million flowed into the stock on the tick-up and $169.06 million flowed out of the stock on the tick-down, for a money net flow of $14.53 million into the stock. Of all equities tracked, Regeneron Pharmaceuticals had the 21st highest net in-flow for the day. Regeneron Pharmaceuticals traded down ($15.52) for the day and closed at $404.56Specifically, Director Arthur F. Ryan sold 2,000 shares of the company’s stock in a transaction dated Tuesday, November 15th. The shares were sold at an average price of $429.34, for a total value of $858,680.00. Following the completion of the transaction, the director now owns 36,500 shares in the company, valued at $15,670,910. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Joseph L. Goldstein sold 2,125 shares of the company’s stock in a transaction dated Monday, November 14th. The stock was sold at an average price of $450.00, for a total transaction of $956,250.00. Following the completion of the transaction, the director now owns 15,125 shares of the company’s stock, valued at approximately $6,806,250. The disclosure for this sale can be found here. 10.40% of the stock is currently owned by company insiders.

A number of research analysts have weighed in on the stock. Piper Jaffray Cos. set a $447.00 price objective on shares of Regeneron Pharmaceuticals and gave the stock a “hold” rating in a research report on Sunday, October 30th. Cowen and Company set a $430.00 price objective on shares of Regeneron Pharmaceuticals and gave the stock a “hold” rating in a research report on Sunday, October 30th. JPMorgan Chase & Co. set a $477.00 price objective on shares of Regeneron Pharmaceuticals and gave the stock a “hold” rating in a research report on Sunday, October 30th. Canaccord Genuity set a $450.00 price objective on shares of Regeneron Pharmaceuticals and gave the stock a “hold” rating in a research report on Sunday, November 6th. Finally, Leerink Swann set a $511.00 price objective on shares of Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research report on Saturday, August 6th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating and twelve have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $468.87.

The firm has a market cap of $42.41 billion, a P/E ratio of 59.03 and a beta of 1.79. The stock has a 50 day moving average price of $381.02 and a 200-day moving average price of $388.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Friday, November 4th. The biopharmaceutical company reported $3.13 earnings per share for the quarter, beating analysts’ consensus estimates of $2.73 by $0.40. The business earned $1.22 billion during the quarter, compared to analyst estimates of $1.29 billion. Regeneron Pharmaceuticals had a net margin of 16.52% and a return on equity of 21.51%. The company’s revenue was up 7.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.47 earnings per share. Equities research analysts predict that Regeneron Pharmaceuticals Inc. will post $11.73 earnings per share for the current year.

Several institutional investors have recently bought and sold shares of REGN. IFP Advisors Inc raised its position in Regeneron Pharmaceuticals by 32.3% in the second quarter. IFP Advisors Inc now owns 328 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 80 shares in the last quarter. Advisory Services Network LLC raised its position in Regeneron Pharmaceuticals by 5,433.3% in the second quarter. Advisory Services Network LLC now owns 332 shares of the biopharmaceutical company’s stock worth $116,000 after buying an additional 326 shares in the last quarter. Alpha Windward LLC raised its position in Regeneron Pharmaceuticals by 11.6% in the third quarter. Alpha Windward LLC now owns 326 shares of the biopharmaceutical company’s stock worth $131,000 after buying an additional 34 shares in the last quarter. Fuller & Thaler Asset Management Inc. purchased a new position in Regeneron Pharmaceuticals during the second quarter worth $140,000. Finally, NEXT Financial Group Inc raised its position in Regeneron Pharmaceuticals by 46.9% in the third quarter. NEXT Financial Group Inc now owns 360 shares of the biopharmaceutical company’s stock worth $145,000 after buying an additional 115 shares in the last quarter. 68.58% of the stock is owned by institutional investors and hedge funds.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.

5 Day Chart for NASDAQ:REGN

Receive News & Stock Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.